When older adults with MS should stop drugs remains unclear
By MS Buddy ·
Summarized from Journal of the neurological sciences, Nov 2026 · PubMed. AI-generated summary. Not medical advice.
24 people · MS specialists in Israel
Research by Keren Regev, Tamir Ben-Hur and 20 colleagues at Neurology Institute, Barzilai Medical Center and 10 other institutions in Israel.
When do MS specialists think older adults should stop treatment?
Key Takeaway
Israeli MS specialists agreed that older adults need treatment decisions based on more than age, but they remained unsure when treatment should stop.

What They Found
Specialists agreed that treatment decisions for older adults with MS should weigh possible benefits and risks. They viewed continuing, reducing, or stopping treatment as possible choices for some older adults whose MS is stable. They remained unsure how best to stop treatment. They also reported uncertainty about treatment decisions when progressive MS shows no current signs of new disease activity. Their views favored considering disease activity, scan results, safety, other health conditions, and patient preferences.
Who Should Care and Why
The study surveyed MS specialists in Israel, not people with MS. It focused on decisions about care for older adults with MS. The specialists discussed whether treatment should continue, be reduced, or stop. They also considered decisions about progressive MS. Their answers show where specialists agreed and where they remained uncertain.
Important Considerations
This was a two-round survey completed by 24 MS specialists. It reports expert opinions, not results from testing treatment choices in patients. You should not read these findings as formal treatment advice or as the views of specialists worldwide.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in Journal of the neurological sciences by et al.. Reproduced from the PubMed record.
The aging population of people with multiple sclerosis (MS) presents growing clinical challenges that are insufficiently addressed by existing evidence. Age-related changes in disease biology, treatment effectiveness, and safety complicate therapeutic decision-making, particularly regarding treatment de-escalation and discontinuation. To describe areas of agreement and uncertainty among Israeli MS specialists regarding clinical decision-making for older adults with MS. A national two-round modified Delphi survey was conducted among 24 MS specialists in Israel. Round 1 included 23 items spanning age-related considerations, late-onset MS (LOMS), treatment continuation, de-escalation and discontinuation, progressive MS, monitoring, vaccination, and treatment decision factors. A structured expert discussion was followed by a focused second round. Consensus definitions were prespecified before response analysis after review of published Delphi methodology and were tailored to item structure. All 24 specialists completed both Delphi rounds. Panel characteristics were subsequently provided by 23 participants (95.8%): median experience in MS care was 15 years (range, 3-35), median annual MS caseload was 500 patients (range, 100-800), 22 practiced primarily in academic or hospital-based settings, and one reported mixed academic and community practice. The panel endorsed age-specific risk-benefit assessment, recognized continuation, de-escalation, and discontinuation as legitimate options in selected stable older patients, and identified persistent uncertainty regarding exit strategies and non-active progressive disease. These findings describe national expert opinion rather than evidence-based recommendations. This national modified Delphi survey describes areas of agreement and uncertainty among Israeli MS specialists. The findings support individualized treatment decisions integrating inflammatory activity, radiologic stability, safety, comorbidity burden, and patient preference, rather than age alone. They should not be interpreted as international consensus or as formal treatment recommendations.
Categories
Explore more research
Related MS research

11/19/2026
A review of one MS stem cell transplant program found most procedures avoided hospital admission. Be
Read More
11/19/2026
A review of 50 studies found wide differences in MS rates across the Americas. MS became more common
Read More
11/20/2026
A study of online MS medication discussions found two main styles: sharing personal experiences and
Read More
11/20/2026
A review of three trials found remotely guided muscle exercises eased urine leaks and bladder overac
Read More
11/18/2026
A review finds limited direct evidence that diet, exercise, or gut microbes affect MS through the bo
Read More
11/19/2026
Interviews with 17 people newly diagnosed with relapsing-remitting MS explored fear, doubt, and unce
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
